Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Telacebec
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : TB Alliance
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the license agreement TB Alliance obtains the exclusive worldwide license to develop and commercialize Q203 (telacebec), a first-in-class orally available cytochrome bc1 inhibitor for the treatment of tuberculosis and some NTM infectio...
Brand Name : Q203
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 03, 2023
Lead Product(s) : Telacebec
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : TB Alliance
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Q702,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Q702 is an orally available novel Axl/Mer/CSF1R inhibitor and is designed to modulate innate immune components leading to T cell activation. Q702 was also shown to increase antigen presentation in the tumor cells demonstrating dual mode of action.
Brand Name : Q702
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 30, 2023
Lead Product(s) : Q702,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Q901
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Q901 is a highly selective CDK7 inhibitor that disrupts tumor cells division cycle progression and blocks DNA damage repair, resulting in tumor cell apoptosis.
Brand Name : Q901
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 01, 2022
Lead Product(s) : Q901
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Telacebec
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Qurient Announces Publication in New England Journal of Medicine of Phase 2 Data for Telacebec
Details : Clinical data supports continued development of telacebec toward the first universal regimen to overcome tuberculosis regardless of drug resistance status.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 26, 2020
Lead Product(s) : Telacebec
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?